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Background. Praziquantel mass drug administration (MDA) is recommended in schistosomiasis-endemic areas. Animal 
models demonstrate Schistosoma parasite resistance to praziquantel after repeated exposure.
Methods. We conducted a parasitological survey in 26 fishing communities in Uganda after 4 years of quarterly (13 communi-
ties) or annual (13 communities) praziquantel MDA, with Schistosoma infection detected by single-stool-sample Kato-Katz. A test 
of cure was done in participants who were positive on both urine circulating cathodic antigen test and 3-sample Kato-Katz. We cal-
culated cure rates (CRs) and egg reduction rates (ERRs) based on 3-sample Kato-Katz and infection intensity using worm-specific 
circulating anodic antigen (CAA) in blood, comparing these between quarterly and annually treated participants.
Results. Single-sample Kato-Katz Schistosoma mansoni prevalence was 22% in 1,056 quarterly treated participants and 34% in 
1,030 annually treated participants (risk ratio, 0.62; 95% confidence interval [CI], 0.40 to 0.94). Among 110 test-of-cure participants, 
CRs were 65% and 51% in annually and quarterly treated villages, respectively (odds ratio, 0.65; 95% CI, 0.27 to 1.58); ERRs were 
94% and 81% (difference, –13%; 95% CI, –48% to 2%). There was no impact of quarterly vs annual praziquantel on S. mansoni by 
CAA.
Conclusions. In this schistosomiasis hot spot, there was little evidence of decreased praziquantel efficacy. However, in the ab-
sence of alternative therapies, there remains a need for continued vigilance of praziquantel efficacy in the MDA era.
Keywords.  drug resistance; mass drug administration; praziquantel; schistosomiasis.
Schistosomiasis affects >250 million people worldwide, mostly 
in sub-Saharan Africa [1, 2]. Praziquantel is the only drug that 
is widely available for the treatment of Schistosoma mansoni 
[3]. It is used as single-dose mono-therapy in mass drug ad-
ministration (MDA) programs for the control of schistosomi-
asis in all endemic settings [4]. However, ~10%–20% of infected 
people are not cured after single-dose treatment [5], depending 
on initial infection intensity.
In Uganda, as in other schistosomiasis-endemic African coun-
tries [6], MDA aims to reduce the intensity of infection and hence 
pathology. Permanent cure and, ultimately, elimination are not ex-
pected in the absence of additional interventions [7, 8]. Individuals 
receiving MDA in high-transmission communities are repeatedly 
exposed to re-infection due to ongoing contamination of water 
and presence of the snail vector, in conjunction with contributing 
factors such as poor sanitation. MDA programs alone have been 
shown to be insufficient for effective control of schistosomiasis [9]; 
other interventions such as WASH (sanitation and personal hy-
giene) and disruption of the parasite life cycle/snail control remain 
key in combatting this health problem. Delivery of such interven-
tions in affected communities is hampered by factors such as the 
unsuitability of introducing molluscicides in large water bodies 
such as Lake Victoria, lack of specific funds to establish good san-
itation facilities such as toilets and safe domestic water systems, 
and challenges in building such facilities in informal settlements 
on sandy lake shores. Hence, MDA continues to be the primary 
weapon in such communities in the fight against this global burden.
The continued use of praziquantel as monotherapy in high-
transmission communities may lead to the development of drug 
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resistance [10], a major international concern. Variation in sus-
ceptibility of Schistosoma species to praziquantel treatment has 
been observed between different human populations [11], and 
studies in mice have demonstrated the potential for inducing 
resistance through drug pressure [12–14].
Among participants of the Lake Victoria Island Intervention 
Study on Worms and Allergy-related diseases (LaVIISWA) 
[15], we conducted a parasitological survey after 4 years of an-
thelminthic MDA intervention. For a subgroup of individuals 
who were infected in this survey, we administered praziquantel 
treatment and assessed cure rate 4 weeks later, comparing those 
who had received quarterly praziquantel treatment with those 
who had received annual praziquantel treatment over the pre-
ceding 4 years.
METHODS
Study Setting
The study was conducted in fishing communities located in the 
Koome islands of Lake Victoria, Uganda, a remote setting ac-
cessible within 2–3 hours from the mainland by powered canoe. 
Schistosomiasis is endemic in the study area, with prevalence 
based on Kato-Katz analysis of a single stool sample estimated at 
52% in the LaVIISWA baseline survey in 2012–2013 (72% prev-
alence by the more sensitive urine circulating cathodic antigen 
[CCA] assay) [16]. Soil-transmitted helminths are also present 
but with lower prevalence, with 2012–2013 estimates of 22% for 
hookworm (based on the more sensitive polymerase chain re-
action test), 10% for Trichuris, and 1% for Ascaris (both based 
on Kato-Katz). Sanitation facilities are limited, with few house-
holds having access to toilets or to water sources other than the 
lake. Community members generally derive their livelihood 
from the lake, and most of the activities on these islands are 
related to fishing. Almost all water for domestic use is obtained 
from the lake, with 1 of the villages having a spring and an-
other having piped water. Hence there is constant exposure of 
village occupants to cercaria, leading to frequent re-infections 
following effective treatment. The communities are comprised 
of temporary wooden structures on land belonging to “land-
lords,” and the population is highly mobile, both between and 
within island villages and between islands and the mainland.
Study Design
The LaVIISWA trial (ISRCTN47196031) was originally de-
signed to assess the effect of 3  years’ intensive vs standard 
anthelminthic treatment on allergy-related outcomes and 
helminth-related pathology. Twenty-six fishing communities 
were randomized in a 1:1 ratio to receive either standard or 
intensive anthelminthic intervention. Standard intervention 
comprised annual praziquantel plus twice-yearly single-dose 
albendazole, whereas intensive intervention comprised quar-
terly praziquantel with use of the extended 60-cm height pole 
[17] to allow treatment of preschool-aged children, for whom 
tablets were crushed and given in juice, plus quarterly triple-
dose albendazole. A  pre-intervention baseline survey and 
3-year outcome survey were conducted, with smaller interim 
parasitological surveys conducted after 1 and 2  years of the 
intervention. Full details of the original trial design [16] and 
results of the outcome survey conducted after 3 years of inter-
vention [15] have been reported.
To assess longer-term effects of MDA on infection prevalence 
and to investigate the possibility of induction of, or selection for, 
praziquantel resistance, the LaVIISWA interventions and fol-
low-up were extended for another year, and at the end of 4 years 
of intensive vs standard treatment, a parasitological survey was 
conducted across all study villages, and a formal test of cure 
was done among selected participants with persistent infection 
from each trial arm.
Study Participants
For the parasitological survey, 70 households were randomly 
selected from each of the 26 fishing communities. All residents 
of selected households were invited to participate in the survey, 
and each was asked to provide a stool sample. After samples 
had been collected, participants taking part in the parasitolog-
ical survey were treated under observation with a single dose of 
praziquantel at 40 mg/kg (estimated by height pole), in accord-
ance with the trial MDA allocation.
For the test-of-cure substudy, which was done in parallel with 
the parasitological survey, 8 communities were selected prag-
matically, with regard to logistics; 4 had received standard in-
tervention, and 4 had received intensive intervention. Within 
these villages, treatment registers were used to identify indi-
viduals who had been resident in the same village throughout 
the 4-year intervention period and who had received at least 
50% of the expected praziquantel treatments during the trial. 
Households containing these individuals were approached in 
a random order, and all eligible individuals in these house-
holds were invited to take part, until the target sample size was 
achieved. Individuals who were not selected for the test-of-cure 
substudy continued to undergo the standard procedures for the 
parasitological survey. From those selected, information about 
age, gender, history of residence in the village, and exposure to 
lake water was obtained, and a screening urine sample was re-
quested to test for Schistosoma infection using a point-of-care 
CCA test (Rapid Medical Diagnostics). Participants who tested 
positive on CCA were requested to provide stool samples on 3 
consecutive days for analysis by the Kato-Katz method, and a 
blood sample was taken from each of these participants for cir-
culating anodic antigen (CAA). After all the samples had been 
collected, participants were treated under observation with 
a single dose of praziquantel at 40  mg/kg. Participants found 
to be Kato-Katz positive at enrollment into the test-of-cure 
substudy based on these 3 stool samples were followed up for 
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4 weeks and requested to provide a further 3 stool samples on 
consecutive days and a further blood sample for serum CAA 
in order to assess cure rates, egg reduction rates, and infection 
intensity based on CAA. At follow-up, after all sample collec-
tion was done, if an individual still had the infection, they were 
treated again with praziquantel.
Diagnostic and Laboratory Methods
For the parasitological survey and for repeated samples at 
baseline and after 4 weeks in the test-of-cure substudy, the 
stool Kato-Katz technique was used to assess for Schistosoma 
mansoni infection. Two slides were prepared immediately from 
stool samples received following the procedures as previously 
described [18], and each slide was read by a different experi-
enced technician to ensure accuracy.
The urine CCA test was used for qualitative detection of 
Schistosoma mansoni infection at enrollment into the test-of-
cure substudy. Each participant was asked to provide a mid-
stream urine sample in a sterile plastic container for the CCA 
test. The CCA was performed according to the kit manufacturer’s 
instructions (Rapid Medical Diagnostics).
We further used the sensitive Schistosoma up-converting 
phosphor lateral flow circulating anodic antigen (UCP-LF-
CAA) to quantify the CAA in sera collected at baseline and 
4 weeks post-treatment from participants in the test-of-cure 
substudy. The applied test format (SCAA20) allowed detection 
of CAA down to a level of 10 pg/mL. Twenty-five samples that 
showed inconsistent results between the Kato-Katz technique 
and SCAA20 were repeated with a higher-sensitivity test format 
(SCAA500), allowing detection down to 1 pg/mL [19, 20].
Ethical Considerations
Ethical approval was given by the Uganda Virus Research 
Institute (reference number GC127), Uganda National Council 
for Science and Technology (reference number HS 1183), and 
London School of Hygiene and Tropical Medicine (reference 
number 6187). Written informed consent was received from 
all adults and emancipated minors and from parents or guard-
ians for children; additional assent was obtained from children 
aged ≥8 years.
Statistical Methods
For the parasitological survey, we anticipated that sampling 70 
households per village would give >80% power to detect a 25% 
relative reduction in S. mansoni prevalence in the intensive trial 
arm compared with standard, assuming a coefficient of varia-
tion of 0.2 and standard arm S. mansoni prevalence of 35%. We 
also anticipated that this would give >80% power to detect an 
absolute increase of 10% in S. mansoni prevalence in the 13 in-
tensively treated study villages between years 3 and 4, assuming 
a coefficient of variation of 0.1 for this analysis. For the test-of-
cure substudy, we anticipated that screening 220 individuals in 
each arm would yield 70 Kato-Katz-positive participants in the 
standard arm and 55 in the intensive arm. Following up these 
individuals after treatment would give ~80% power to detect a 
difference in cure rate of 70% in the standard arm [21] vs 40% 
in the intensive arm.
Characteristics of parasitological survey participants and 
test-of-cure substudy participants were summarized. The effect 
of 4 years’ intensive vs standard anthelminthic intervention on 
S. mansoni prevalence was assessed using a cluster-level anal-
ysis, as described previously [15]. Briefly, the risk ratio was 
calculated as the mean of the cluster-specific proportions with 
S. mansoni infection in the intensive arm divided by the corre-
sponding mean in the standard arm, with the 95% confidence 
interval (CI) calculated using a Taylor series approximation 
for the standard error and P values from unpaired t tests. The 
prevalence of S. mansoni infection was compared between time 
points using paired t tests of cluster-level proportions.
Cure rate was defined as the proportion of participants who 
were Kato-Katz negative on all 3 samples at follow-up, out of 
those positive for S. mansoni on at least 1 stool sample at base-
line. Cure rates were compared between the standard and in-
tensive arms using chi-square tests, with further comparisons 
adjusting for age, gender, and baseline infection intensity using 
logistic regression. Egg reduction rates were calculated as 100* 
(1 – [mean arithmetic egg count at follow-up/mean arithmetic 
egg count at baseline]) [22, 23], with 95% confidence inter-
vals for ERRs and the difference between ERRs (intensive vs 
standard trial arms) calculated using a bias-corrected boot-
strapping approach with 1000 permutations. Changes in CAA 
concentration between baseline and 4 weeks post-treatment 
were compared between the arms using mixed-effects linear re-
gression, with an interaction term between time and trial arm 
fitted to assess whether the change over time differed between 
the 2 trial arms.
RESULTS
Parasitological Survey
Between March 21 and November 16, 2017, a total of 1790 
households were randomly selected to take part in the parasito-
logical survey (2 villages contained fewer than the target sample 
size of 70 households; in these villages, all households were in-
cluded). Among these, a total of 2086 individuals, representing 
1078 households, provided stool samples. The predominant 
reasons for not taking part were that the household was unoc-
cupied or the occupants were absent upon repeated visits. The 
median (interquartile range) age of participants providing stool 
samples was 26 (8–36) years in the standard intervention arm 
and 27 (9–36) years in the intensive intervention arm; 52% and 
51% were male in the standard and intensive arms, respectively.
The prevalence of S. mansoni based on Kato-Katz analysis of 
a single stool sample was 28% overall, 34% in the standard arm, 
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and 22% in the intensive arm (risk ratio for effect of intensive vs 
standard anthelminthic intervention, 0.62; 95% confidence in-
terval, 0.40–0.94; P = .02). Figure 1 shows the overall infection 
prevalence and the proportion with low, moderate, and heavy 
infections over the 4  years of intervention by treatment arm. 
The prevalence of S. mansoni infection in the intensive arm de-
clined by a small amount during the fourth year of intervention 
(3-year prevalence, 23.1%; 4-year prevalence, 21.6%; P = .21), 
with a somewhat greater decline seen in the standard interven-
tion arm (3-year prevalence, 38.6%; 4-year prevalence, 34.2%; 
P = .08). There was no statistical difference in these declines be-
tween trial arms (Pinteraction = .47).
Test-of-Cure Substudy
Figure  2 shows the flow of participants through the test-of-
cure substudy. Of the 410 participants screened from 8 villages, 
214 (52%) were positive by the urine CCA test, 101 (46%) of 
218 screened in the standard trial arm and 113 (59%) of 192 
screened in the intensive trial arm. Sixty-nine (68%) of the 101 
CCA-positive participants in the standard arm were KK posi-
tive (on at least 1 of 3 stool samples) and enrolled for follow-up, 
of whom 49 (71%) were seen at follow-up and provided stool 
samples. Seventy-seven (68%) of the 113 CCA-positive partici-
pants in the intensive trial arm were KK positive (on at least 1 of 
3 stool samples) and enrolled for follow-up, of whom 61 (79%) 
were seen and provided stool samples.
Characteristics of participants who were enrolled but not 
seen at follow-up and of those who were enrolled and fol-
lowed up, stratified by trial arm, are shown in Table 1. Over 
two-thirds of enrolled participants were male, and the ma-
jority had contact with the lake every day. Successful fol-
low-up in the cure rate substudy was higher for younger 
participants (preschool and school-aged) and somewhat 
lower for males than females. There were some differences 
between the standard and intensive trial arm participants for 
those who were followed up, with a higher proportion of fe-
males and school-aged participants in the intensive arm com-
pared with the standard arm.
Table 2 shows CRs and ERRs stratified by trial arm. In the 
standard arm, 32 of the 49 participants seen at follow-up 
were KK negative on all 3 stool samples, yielding a cure rate 
of 65%. In the intensive arm, 31 of 61 seen at follow-up were 
KK negative, yielding a cure rate of 51% and a crude odds 
ratio (intensive vs standard arm) of 0.55 (95% CI, 0.25 to 1.19; 
P = .13). After adjusting for baseline infection intensity, sex, 
and age, the estimated odds ratio was 0.65 (95% CI, 0.27 to 
1.58; P = .35). Egg reduction rates were 93.7% (95% CI, 84.9% 
to 97.7%) in the standard arm and 80.6% (95% CI, 43.8% to 
93.7%) in the intensive arm, with the difference in ERR esti-
mated as –13.1% (95% CI, –47.9% to 2.2%). CAA was meas-
ured in 90 participants (37 standard arm, 53 intensive arm) 
who provided sera at baseline and 4 weeks post-treatment. 
Figure 3 shows the log CAA concentration for cure rate study 
participants at baseline and 4 weeks post-treatment. In both 
trial arms, the median CAA concentration reduced following 
treatment, with a slightly smaller reduction seen in the inten-
sive arm participants, but there was no statistical evidence of 
interaction (P = .35).
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Figure 1. Prevalence and intensity of Schistosoma mansoni infection (as detected by Kato-Katz examination of a single stool sample) over 4 years of anthelminthic inter-
vention, by trial arm.
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Figure 2. Flowchart of participants through cure rate study.
Table 1. Characteristics of Participants Enrolled and Followed up in the Cure Rate Study
Characteristic
Enrolled, not  
Followed up  
(n = 36), No. (%)
Enrolled, Followed 
up (n = 110), No. (%) P Valuea
Seen at Follow-up and Included in Cure Rate Study Results
P Valueb
Standard Arm (n = 49),  
No. (%)
Intensive Arm (n = 61),  
No. (%)
Sexc
 Male (n = 100) 28 (28) 72 (72)  37 (77) 35 (57)  
 Female (n = 45) 8 (18) 37 (82) .187 11 (23) 26 (43) .031
Age, yc
 <15 (n = 63) 8 (13) 55 (87)  19 (40) 36 (60)  
 15–34 (n = 46) 15 (33) 31 (67)  18 (38) 13 (22)  
 35 + (n = 35) 13 (37) 22 (63) .010 11 (23) 11 (18) .091
Main occupationc
 Child/student (n = 63) 7 (11) 56 (89)  19 (42) 37 (65)  
 Fisherman (n = 41) 13 (32) 28 (68)  16 (36) 12 (21)  
 Other (n = 34) 16 (47) 18 (53) <.001 10 (22) 8 (14) .073
Treated for malaria in past yearc
 No (n = 69) 23 (33) 46 (67)  18 (44) 28 (54)  
 Yes (n = 60) 13 (22) 47 (78) .141 23 (56) 24 (46) .341
Frequency of lake contactc
 Every day (n = 119) 29 (24) 90 (76)  40 (85) 50 (86)  
 Less than every day 
(n = 22)
7 (32) 15 (68) .462 7 (15) 8 (14) .873
No. of praziquantel treatments in past 4 yearsc
 Mean (SD) 4.4 (3.2) 6.5 (4.3) .010 4.0 (3.3) 7.9 (4.4) <.001
Baseline infection intensity
 Light (n = 87) 22 (25) 65 (75)  26 (53) 39 (64)  
 Moderate (n = 35) 8 (23) 27 (77)  14 (29) 13 (21)  
 Heavy (n = 24) 6 (25) 18 (75) .960 9 (18) 9 (15) .511
aP value for differences between those followed up and not followed up. 
bP value for differences between standard and intensive arm participants who were followed-up. 
cMissing values for sex (1 participant), age (2 participants), occupation (8 participants), malaria treatment (17 participants), lake contact (5 participants), praziquantel treatment (18 participants).
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DISCUSSION
In these Lake Victoria island communities, S. mansoni preva-
lence in villages receiving 4 years of community-wide quarterly 
praziquantel treatment was 38% lower than in villages re-
ceiving annual treatment. The greatest reduction in S. mansoni 
prevalence in quarterly treated villages occurred in the first 
year of the intervention and was followed by smaller reduc-
tions in subsequent years and a plateau in prevalence of mod-
erate–heavy infections, in contrast to annually treated villages 
where S.  mansoni prevalence declined approximately linearly 
throughout the 4 years of intervention. Our formal test-of-cure 
indicated some suggestion of a reduction in cure rates and egg 
reduction rates among residents of quarterly treated villages 
compared with those in annually treated villages, although no 
difference was seen using the more sensitive CAA method.
Previous trials focusing on school children in a high-
prevalence setting in Tanzania [24] and a low- to moderate-
prevalence setting in Kenya [25] found no additional benefit of 
annual compared with biennial MDA for reducing prevalence. 
Our study suggests that more intensive (quarterly) treatment 
can reduce prevalence compared with an annual treatment 
strategy. However, after 4 years of intensive quarterly treatment 
with an average treatment coverage by treatment round of 63% 
[15], the prevalence of S. mansoni reduced from 49% at base-
line to a still relatively high level of 22%, based on Kato-Katz 
analysis of a single stool sample. This is a relative reduction of 
55%, demonstrating that our study setting might be considered 
a persistent hot spot [26].
In the cure rate substudy, the observed egg reduction rate of 
80.6% was below the 90% threshold of optimal praziquantel ef-
ficacy set by the World Health Organization (although the 95% 
confidence interval does include 90%) [27], and there was some 
evidence that ERRs based on KK were reduced in villages that 
had received quarterly compared with annual praziquantel, al-
though results from the more sensitive CAA test did not show 
evidence of such a reduction. Although convincing evidence for 
the broader emergence of resistance in countries where MDA 
has been used for many years is lacking, continued vigilance is 
needed to ensure that praziquantel remains an effective drug for 
the treatment of schistosomiasis.
A major limitation of the cure rate substudy was that the 
planned sample size was not achieved, resulting in reduced 
power to detect differences between the 2 trial arms. This was 
predominantly due to difficulties in locating cure rate study 
participants for follow-up investigations in this highly mobile 
study population, with particular difficulties in locating men of 
working age. Further studies based on larger sample sizes and 
parasite genetic analyses are required to further test this out-
come. We were not able to assess re-infection rates in this study. 
However, as the follow-up period in this study was 1  month, 
it is unlikely that the ERRs and cure rates were influenced by 
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re-infections given the life cycle of the parasite. We cannot rule 
out the possibility that immature parasites, not susceptible to 
praziquantel, may have been present at enrollment and sub-
sequently matured, contributing to the infections detected at 
follow-up.
In conclusion, 4  years of quarterly praziquantel reduced 
schistosomiasis prevalence compared with annual treatment, 
although infection following both strategies remained common. 
Continued vigilance, for example, through periodic investiga-
tion of cure rate and ERR, should be maintained to ensure that 
parasites do not develop tolerance to praziquantel in ongoing 
MDA programs. Complementary or alternative strategies are 
needed to further reduce the schistosomiasis burden.
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Figure 3. Schistosoma mansoni circulating anodic antigen (CAA) results at baseline and 4 weeks post-treatment among cure rate study participants, by trial arm. Each line 
represents a single participant; the thick red lines represent the median log CAA at each time point.
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